优泌乐与优泌林R在初诊2型糖尿病胰岛素泵治疗中的疗效对比  被引量:4

Comparison between the Effects of Insulin Lispro and Humulin R Via Continuous Subcutaneous Insulin Infusion Pump on Hyperglycemia in Newly-diagnosed Type 2 Diabetes

在线阅读下载全文

作  者:杨萍[1] 魏祎[1] 牛瑶[1] 

机构地区:[1]新乡医学院第三附属医院,河南新乡453003

出  处:《中国医学创新》2014年第7期48-50,共3页Medical Innovation of China

摘  要:目的:比较胰岛素泵输注赖脯胰岛素(优泌乐)与重组人胰岛素(优泌林R)治疗初诊2型糖尿病的疗效及安全性。方法:选择45例本院初诊2型糖尿病患者行胰岛素泵强化治疗,并按随机数字表法分为优泌乐组和优泌林R组,比较两组各点血糖、血糖达标时间、血糖达标时胰岛素用量及低血糖发生率。结果:优泌乐组的血糖达标时间较优泌林R组短,胰岛素用量也较少,餐后血糖值更低,差异均有统计学意义(P<0.05);但两组餐前血糖及睡前血糖比较差异无统计学意义(P>0.05)。结论:用胰岛素泵输注优泌乐和优泌林R均能安全、有效的控制初诊2型糖尿病高血糖状态,但优泌乐组血糖达标时间更短,餐后血糖控制更佳,所需胰岛素量更少。Objective:To compare the efficacy and safety of insulin Lispro and Humulin R via continuous subcutaneous insulin infusion pump on hyperglycemia in newly-diagnosed 2 diabetes. Method:45 patients accepted a 2-week course of intensive CsII were selected. They were divided into group A(n=25)and group B(n=20)according to random number table method. The group A was treated with insulin Lispro,the group B was treated with Humulin R. The therapeutic effects were measured after therapy. Result:The time for good glycemia control was shorter in the group A than that in the group B(P〈0.05);the mean of three postprandial blood glucose were significantly lower in the group A than that in the group B,with lower total insulin dosage,the differences were statistically significant(P〈0.05);but no differences in blood glucose between the two groups were observed in bedtime and before three meals(P&gt;0.05). Conclusion:Insulin Lispro via continuous subcutaneous insulin infusion pump is as efficacious and safe as Humulin R in controlling hyperglycemia in newly-diagnosed type 2 diabetes,but insulin Lispro provides a more effective and faster control of postprandial hyperglycemia with less insulin used.

关 键 词:糖尿病 2型 胰岛素泵 优泌林R 赖脯胰岛素 

分 类 号:R587.1[医药卫生—内分泌]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象